News & Events

Press Releases

March 15 2018

Vasopharm Provides Update on Phase III Traumatic Brain Injury Trial

50% of patients enrolled in trial triggers interim data review. vasopharm GmbH, a privately held biopharmaceutical company, today announced that it has recruited half of the 220 patients in the ongoing, pivotal European NOSTRA III (NO Synthase in TRAumatic Brain Injury) clinical trial. This milestone triggers an interim review by the Data Monitoring Committee (DMC) in line with the agreed study protocol. Allowing for the six month extended Glasgow Outcome Scale (eGOS) evaluation for the 110th eligible patient recruited, the company expect feedback from the DMC in Q4 2018.

Read on Download PDF
November 8 2016

vasopharm appoints Chief Medical Officer

vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, today announced the appointment of Dr Irina Antonijevic as Chief Medical Officer. In this newly-created role, Dr Antonijevic will be responsible for advancing the clinical development of vasopharm’s lead ongoing program, VAS203.

Read on Download PDF
September 6 2016

vasopharm Announces Enrolment of First Patient In Phase III Traumatic Brain Injury (TBI) Trial

vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, today announced that the first patient has been enrolled in to the NOSTRA III (NO Synthase in TRAumatic Brain Injury) trial – a phase III clinical trial assessing efficacy and safety of Ronopternin (VAS203) for the treatment of moderately to severely injured closed head traumatic brain (TBI) injury patients.

Read on Download PDF
January 21 2016

vasopharm Announces EUR 20 million Fundraising to Progress Treatment for Traumatic Brain Injury

vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, today announced it has successfully raised EUR 20 million of new capital. The financing was co-led by existing investors Entrepreneurs Fund, Heidelberg Capital Private Equity and new investor, UK based Fort Rock Capital. Existing investors Bayern Kapital and funds advised by Hanseatic Asset Management LBG also participated in the round. Dr Mario Alberto Accardi, Venture Partner at Fort Rock Capital will be joining the Board of the company as a Non-Executive Director.

Read on Download PDF
October 22 2013

vasopharm Reports Endorsement of Phase III Trial Design in Traumatic Brain Injury by European Medicines Agency

vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebro- and cardiovascular diseases, today announced the positive outcome of a scientific advice meeting with the European Medicines Agency (EMA). The EMA’s Committee for Medicinal Products for Human Use (CHMP) has agreed to all major items of vasopharm’s proposed protocol for the realisation of a European Phase III study of VAS203 in patients suffering from traumatic brain injury (TBI).

Read on Download PDF
June 13 2013

vasopharm Closes Series F Financing Round

vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebro- and cardiovascular diseases, today announced the successful completion of a Series F financing round totalling €5 million (~ US$ 6.5 million). The round was led by existing investors HeidelbergCapital Private Equity and Entrepreneurs Fund (EF Investments S.à.r.l.). Bayern Kapital, another existing investor, also participated in the Series F round. The consortium was joined by new investors Hanseatic Asset Management LBG and Dr Andrew Clark, Chairman of the Board of vasopharm. The new consortium also acquired the shares of one of the founding investors seeking to exit.

Read on Download PDF